These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27565406)

  • 1. In Reply to the Letter to the Editor Titled "Which Epidemiological Factors Have the Most Influence on the EGFR Mutation Frequency in Lung Adenocarcinoma?".
    Leduc N; Sabourin JC; Molinié V
    J Thorac Oncol; 2016 Sep; 11(9):e114-5. PubMed ID: 27565406
    [No Abstract]   [Full Text] [Related]  

  • 2. Which Epidemiological Factors Have the Most Influence on the EGFR Mutation Frequency in Lung Adenocarcinoma?
    Elghissassi I; Boutayeb S; Errihani H
    J Thorac Oncol; 2016 Sep; 11(9):e113-4. PubMed ID: 27565405
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.
    Beau-Faller M; Cadranel J
    Ann Oncol; 2016 Feb; 27(2):359-60. PubMed ID: 26658890
    [No Abstract]   [Full Text] [Related]  

  • 5. EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.
    Berg J; Fjellbirkeland L; Suhrke P; Jebsen P; Lund-Iversen M; Kleinberg L; Helgeland L; Brustugun OT; Helland Å
    Acta Oncol; 2016; 55(2):149-55. PubMed ID: 26313507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.
    Le T; Sailors J; Oliver DH; Mayer M; Hoskin S; Gerber DE
    Lung Cancer; 2017 Mar; 105():14-16. PubMed ID: 28236979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between EGFR Mutations and Pathological Classification and 
Specimen of Lung Adenocarcinoma].
    Kang L; Zheng J; Zhu X
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
    Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
    Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): A report of 106 patients from Kolkata.
    Chatterjee K; Ray A; Chattopadhyay B
    Indian J Cancer; 2017; 54(1):305-307. PubMed ID: 29199710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma.
    Deng H; Liu J; Duan X; Liu Y
    Pathol Res Pract; 2018 Mar; 214(3):450-454. PubMed ID: 29496311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma.
    Tseng JS; Wang CL; Yang TY; Chen CY; Yang CT; Chen KC; Hsu KH; Tsai CR; Chang GC
    Lung Cancer; 2015 Dec; 90(3):472-6. PubMed ID: 26474957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
    Mohar B; Smojver Ježek S; Rajković Molek K; Štemberger C; Kurpis M; Kupanovac Ž; Samaržija M; Jonjić N; Grahovac B
    Cytopathology; 2016 Dec; 27(6):444-451. PubMed ID: 26990359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
    Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
    Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
    Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbian patients with lung adenocarcinoma.
    Zaric B; Stojsic V; Kovacevic T; Sarcev T; Tepavac A; Jankovic R; Spasic J; Radosavljevic D; Zarogoulidis P; Vukobradovic-Djoric N; Perin B
    J Thorac Oncol; 2014 Sep; 9(9):1406-10. PubMed ID: 25122436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.
    Chen HY; Liu CH; Chang YH; Yu SL; Ho BC; Hsu CP; Yang TY; Chen KC; Hsu KH; Tseng JS; Hsia JY; Chuang CY; Chang CS; Li YC; Li KC; Chang GC; Yang PC
    Oncotarget; 2016 Feb; 7(8):9017-25. PubMed ID: 26824984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.